Skip to content

Herbal medicine in renal stone

Safety and efficacy of a polyherbal formulation in patients with calcium renal stones: A randomized, clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180923041093N8
Enrollment
50
Registered
2026-05-08
Start date
2026-05-22
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrolithiasis. Calculus of kidney

Interventions

Intervention 1: Intervention group: IA specific amount of black pepper, black seed, black cumin, and ginger rhizome powder is ground and mixed with honey. The patient consumes 5 grams of this mixture

Sponsors

Zahedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Kidney stones 5 mm or larger in the lower pole of the kidney Age between 18 and 60 years old

Exclusion criteria

Exclusion criteria: severe urinary tract infection acute renal injury CKD diabetes concomitant use of herbal remedies to dissolve kidney stones such as Sankol®, Rowatinex®, Cystone®, Lithorex-B® or Urtica ZardBand® pregnant or lactating women patients with coagulation problems or taking anticoagulant medications a history of ulcers or erosions in the gastrointestinal tract

Design outcomes

Primary

MeasureTime frame
Renal stone size. Timepoint: At the baseline (before the intervention) and 10 days after starting the drug. Method of measurement: Ultrasound.

Secondary

MeasureTime frame
BUN. Timepoint: At baseline (before the intervention) and 10 days after starting the drug. Method of measurement: blood test.;Serum creatinine. Timepoint: At baseline (before the intervention) and 10 days after starting the drug. Method of measurement: blood test.;Serum calcium. Timepoint: At baseline (before the intervention) and 10 days after starting the drug. Method of measurement: blood test.;Liver enzymes. Timepoint: At baseline (before the intervention) and 10 days after starting the drug. Method of measurement: blood test.;Urine specific gravity. Timepoint: At baseline (before the intervention) and 10 days after starting the drug. Method of measurement: Urine analysis.;24 h urine volume. Timepoint: At baseline (before the intervention) and 10 days after starting the drug. Method of measurement: Graduated container.;24 h urine calcium. Timepoint: At baseline (before the intervention) and 10 days after starting the drug. Method of measurement: Urine analysis.;24 h urine magnesium. Timepoint: At baseline (before the intervention) and 10 days after starting the drug. Method of measurement: Urine analysis.;Number of analgesics used. Timepoint: On days 1, 2, 3, 4, and 5 after the start of the intervention. Method of measurement: Asking the patient.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHabib Ghaznavi

Zahedan University of Medical Sciences

dr.ghaznavi@zaums.ac.ir+98 54 3337 2151

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026